Samantree Medical SA has published clinical data demonstrating a significant reduction in re-operations in breast-conserving surgery using its novel ultra-fast confocal microscopy technology. The study on its medical imaging platform, the Histolog scanner, has just been published in The Breast.
Researchers from Incyte Research Institute presented the discovery of a cyclin-dependent kinase 2 (CDK2) inhibitor, INCB-123667, being developed for the treatment of cyclin E dysregulated cancers.
Orion Corp. has described transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer, musculoskeletal and neuropathic pain.
Duality Biologics (Suzhou) Co. Ltd. has presented data describing the discovery and preclinical results of DB-1303, an antibody-drug conjugate containing a trastuzumab biosimilar targeting HER2 (BAT0606), an exatecan derivative payload with topoisomerase I inhibitory activity (P1003) and an enzymatic ally cleavable tetrapeptide-maleimide-linker (payload-linker named L101P1003).
Oncores Medical Pty Ltd. reported positive data from its first in-cavity trial of its quantitative micro-elastography (QME) imaging system, a hand-held imaging tool that helps surgeons differentiate between cancerous and healthy breast tissue at the point of surgery.
HER2 is a receptor tyrosine kinase and well-established oncogenic driver with mutations present in various types of tumors such as bladder urothelial carcinoma, uterine corpus endometrial carcinoma, stomach adenocarcinoma and breast cancer.
Hainan Sparkle Therapeutics Co. Ltd. has described ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Turnstone Biologics Corp. has received IND clearance from the FDA for the company's lead selected tumor-infiltrating lymphocyte (TIL) therapy program, TIDAL-01.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase-binding moiety covalently bonded to estrogen receptor-α (ERα)-targeting moiety through a linker reported to be useful for the treatment of breast cancer and infections.
Mablink Bioscience SAS., Université Claude Bernard Lyon 1 and Centre National de la Recherche Scientifique have patented antibody-drug conjugates consisting of antibodies covalently linked to therapeutic drugs through an enzyme-triggered self-immolative linker reported to be useful for the treatment of cancer.
